HK1162306A1 - Replication-defective flavivirus vaccines and vaccine vectors - Google Patents

Replication-defective flavivirus vaccines and vaccine vectors

Info

Publication number
HK1162306A1
HK1162306A1 HK12102646.0A HK12102646A HK1162306A1 HK 1162306 A1 HK1162306 A1 HK 1162306A1 HK 12102646 A HK12102646 A HK 12102646A HK 1162306 A1 HK1162306 A1 HK 1162306A1
Authority
HK
Hong Kong
Prior art keywords
replication
vaccine vectors
flavivirus vaccines
defective flavivirus
defective
Prior art date
Application number
HK12102646.0A
Other languages
English (en)
Chinese (zh)
Inventor
Konstantin V Pugachev
Alexander A Rumyantsev
Maryann Giel-Moloney
Harold Kleanthous
Original Assignee
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc
Publication of HK1162306A1 publication Critical patent/HK1162306A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102646.0A 2008-03-14 2012-03-15 Replication-defective flavivirus vaccines and vaccine vectors HK1162306A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6945108P 2008-03-14 2008-03-14
US9281408P 2008-08-29 2008-08-29
PCT/US2009/001666 WO2009114207A2 (en) 2008-03-14 2009-03-16 Replication-defective flavivirus vaccines and vaccine vectors

Publications (1)

Publication Number Publication Date
HK1162306A1 true HK1162306A1 (en) 2012-08-31

Family

ID=41065743

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102646.0A HK1162306A1 (en) 2008-03-14 2012-03-15 Replication-defective flavivirus vaccines and vaccine vectors

Country Status (16)

Country Link
US (2) US8815564B2 (xx)
EP (1) EP2265284A4 (xx)
JP (1) JP5779352B2 (xx)
KR (1) KR101719316B1 (xx)
CN (2) CN105039266A (xx)
AU (1) AU2009223727B2 (xx)
BR (1) BRPI0908936A2 (xx)
CA (1) CA2717499A1 (xx)
EA (2) EA201591888A1 (xx)
HK (1) HK1162306A1 (xx)
IL (1) IL208147A (xx)
MX (1) MX2010010034A (xx)
SG (1) SG188891A1 (xx)
UA (1) UA103316C2 (xx)
WO (1) WO2009114207A2 (xx)
ZA (1) ZA201006437B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
CN105039266A (zh) * 2008-03-14 2015-11-11 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
EP2257308A4 (en) * 2008-03-27 2012-06-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRUS VECTORS
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
CN107126557A (zh) * 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2011119716A2 (en) * 2010-03-24 2011-09-29 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2012003320A2 (en) 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
AU2012207089B2 (en) 2011-01-20 2016-04-14 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae
CN102181408A (zh) * 2011-01-30 2011-09-14 中国检验检疫科学研究院 圣路易斯脑炎病毒样颗粒的制备方法及其应用
CA2836501A1 (en) 2011-07-12 2013-01-17 Gwong-Jen J. Chang Identification of a west nile virus cd4 t cell epitope and use thereof
WO2013106337A1 (en) * 2012-01-09 2013-07-18 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
WO2013116770A1 (en) * 2012-02-01 2013-08-08 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
WO2013138776A1 (en) * 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US20140271708A1 (en) * 2013-03-15 2014-09-18 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
SG11201607287XA (en) * 2014-03-01 2016-09-29 Univ Texas Recombinant isfahan viral vectors
EP3158061B1 (en) 2014-06-20 2019-08-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/dengue viruses and methods of use
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
BR112017025954A2 (pt) * 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
WO2018060771A1 (en) 2016-09-30 2018-04-05 Sanofi Pasteur Live attenuated chimeric zika virus and its use as an immunogenic composition
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
WO2018231690A1 (en) * 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
GB201814563D0 (en) * 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用
CN110157685B (zh) * 2019-05-20 2022-11-01 中国科学院武汉病毒研究所 一种复制缺陷西尼罗病毒的制备方法及应用
JP7221995B2 (ja) * 2019-05-28 2023-02-14 チェンマイ・ユニバーシティ フラビウイルスの成熟ウイルス様粒子
WO2021048003A1 (en) * 2019-09-13 2021-03-18 Katholieke Universiteit Leuven Chimeric filovirus vaccines

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393201A (en) 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus
JPS6011428A (ja) 1983-02-01 1985-01-21 ジエネンテク，インコ−ポレイテツド 狂犬病ワクチン
US5830477A (en) * 1984-04-25 1998-11-03 Transgene S.A. Vaccine against rabies and process for preparation thereof
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
DE3787864T2 (de) 1986-08-13 1994-02-10 Miles Inc Karzinoembryonisches Antigen kodierende cDNS.
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
CA1340221C (en) 1988-01-29 1998-12-15 Thomas Frank Bumol Vectors, compounds and method for expression of a human adenocarcinoma antigen
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
JPH03139286A (ja) * 1989-10-25 1991-06-13 Nippon Seibutsu Kagaku Kenkyusho 狂犬病ウイルスｇ蛋白質を産生する組み換えバキュロウイルス及びｇ蛋白質の製造方法
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
ES2206446T3 (es) 1991-05-06 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo.
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
JP4504464B2 (ja) * 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
AU9572098A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
JP2002500003A (ja) 1997-11-28 2002-01-08 ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス フラビウイルスの発現および送達のシステム
CA2341018C (en) 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU1940301A (en) * 1999-12-03 2001-06-12 Yale University Tick antigens and compositions and methods comprising them
WO2002072803A2 (en) 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
ES2439724T3 (es) 2001-06-01 2014-01-24 Sanofi Pasteur Biologics, Llc Vectores de flavivirus quiméricos
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
AU2003267851B2 (en) * 2002-10-09 2007-07-05 Young-Min Lee Novel full-length genomic RNA of Japanese encephalitis virus, infectious JEV CDNA therefrom, and use thereof
CN1322120C (zh) * 2003-03-20 2007-06-20 上海天甲生物医药有限公司 乙肝乙脑双价疫苗
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
JP2007535918A (ja) * 2004-04-09 2007-12-13 ワイス 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物
JP2007532656A (ja) * 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
WO2006017206A2 (en) * 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
EP1861491A4 (en) * 2005-02-16 2009-07-08 Replikun Biotech Pty Ltd FLAVIVIRUS REPLICON CONSTRUCTS FOR ANTITUMOR THERAPY
ES2478303T3 (es) 2005-04-24 2014-07-21 Sanofi Pasteur Biologics, Llc Vacunas de flavivirus recombinantes
AU2007217352B2 (en) * 2006-02-27 2013-09-26 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
BRPI0714721A2 (pt) 2006-07-14 2013-04-24 Sanofi Pasteur Biologics Co construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial
US8486417B2 (en) 2007-01-31 2013-07-16 Sanofi Pasteur Biologics, Llc Recombinant bicistronic Flavivirus vectors
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
CA2676719A1 (en) 2007-02-09 2008-08-21 Sanofi Pasteur Biologics Co. Viral vectors and methods of use
JP5537419B2 (ja) 2007-05-07 2014-07-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 二成分ゲノムフラビウイルスおよびその使用
CN105039266A (zh) * 2008-03-14 2015-11-11 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
CA2755257A1 (en) 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus

Also Published As

Publication number Publication date
UA103316C2 (uk) 2013-10-10
US20110135686A1 (en) 2011-06-09
CA2717499A1 (en) 2009-09-17
ZA201006437B (en) 2016-03-30
EA201591888A1 (ru) 2016-05-31
EP2265284A2 (en) 2010-12-29
WO2009114207A3 (en) 2010-01-07
WO2009114207A2 (en) 2009-09-17
IL208147A (en) 2016-02-29
CN102202687B (zh) 2015-07-29
JP2011516040A (ja) 2011-05-26
CN102202687A (zh) 2011-09-28
BRPI0908936A2 (pt) 2017-03-28
KR20110002845A (ko) 2011-01-10
US8815564B2 (en) 2014-08-26
AU2009223727B2 (en) 2014-09-11
MX2010010034A (es) 2010-12-06
EP2265284A4 (en) 2012-04-25
KR101719316B1 (ko) 2017-03-24
CN105039266A (zh) 2015-11-11
EA023888B1 (ru) 2016-07-29
IL208147A0 (en) 2010-12-30
SG188891A1 (en) 2013-04-30
US20130243812A1 (en) 2013-09-19
AU2009223727A1 (en) 2009-09-17
JP5779352B2 (ja) 2015-09-16
EA201001491A1 (ru) 2011-06-30
US9217158B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
HK1162306A1 (en) Replication-defective flavivirus vaccines and vaccine vectors
IL215389A0 (en) Pneumococcal vaccine and uses thereof
PL2655604T3 (pl) Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
IL215430A (en) Immunogenic and antiviral vaccines and their use
ZA201005742B (en) Polypeptide vaccine and vaccination strategy against mycobacterium
HK1245334A1 (zh) 改善的用於人乳頭狀瘤病毒的疫苗及其使用方法
ZA201105656B (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2408477A4 (en) REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
IL219976A0 (en) Imp-3 oligopeptides and vaccines including the same
EP2473188A4 (en) PROTEIN MATRIX VACCINES WITH IMPROVED IMMUNOGENICITY
IL214435A0 (en) Foxm1 peptides and vaccines containing the same
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
EP2117589A4 (en) FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
ZA201104013B (en) Recombinant inactivated viral vector vaccine
ZA201103645B (en) Single-time vaccines
EP2491946A4 (en) ADJUVANT FOR VACCINES, VACCINES COMPRISING SAME, AND USES THEREOF
EP2430039A4 (en) TTK-PEPTIDES AND VACCINES CONTAINING THEM
AP2013006972A0 (en) Adenovirus serotype 26 and serotype 35 filovirus vaccines
IL213318A0 (en) C1orf59 peptides and vaccines including the same
GB0818065D0 (en) Immunogenic peptides and uses thereof
HRP20180744T1 (hr) Terapeutska cjepiva
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
TWI346557B (en) Adjuvant and vaccine includes the same
GB0801424D0 (en) Therapeutic vaccines

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200312